Deutsch

Dr Morton Douglas

Rechtsanwalt (Lawyer) and Partner

Freiburg

Guest lecturer in Intellectual Property Law at Eberhard Karls Universität Tübingen

Dr Morton Douglas has been working as a lawyer in our Freiburg office since 2004 and became a partner in 2010. He advises clients primarily on trademark and design protection in the areas of research, the development of application strategies, portfolio consulting, defense in official and infringement proceedings, licensing agreements, corporate identity law, and titles and domains. In patent law, he advises and represents clients in litigation and licensing agreements. He also advises on competition law, pharmaceutical advertising law, pharmacy and drug law, data protection law, and crisis management in press law.

Languages

  • German
  • English

Contact

V-Card

Practices

Awards

Handelsblatt & Best Lawyers 2027 JUVE Handbook of Commercial Law Firms 2025/26

Publications

  • Grenzenlose Telemedizin? (Telemedicine without limits?) Commentary on the judgment of the European Court of Justice of September 11, 2025, Ref. C 115/24, A&R 2025, p. 240
  • Arzneimittelpreisbindung: Chance vertan? (Fixed drug prices: a missed opportunity?) Commentary on the ruling of the Federal Court of Justice of July 17, 2025, Ref. I ZR 74/24, A&R 2025, p. 202
  • Im Rausch der Blüten – Risiken und Nebenwirkungen bei der digitalen Verschreibung von Medizinalcannabis (Intoxicated by the flowers – risks and side effects of the digital prescription of medicinal cannabis), A&R 2024, p. 304
  • Rückkehr zur grenzüberschreitenden Arzneimittelpreisbindung? (Return to cross-border fixed pharmaceutical prices?), comment on the judgment of the Higher Regional Court of Munich of March 7, 2024, Ref.: 6 U 1509/14, A&R 2024, p. 122
  • „Wer hat‘s vertrieben? Zur Abgrenzung zwischen Apotheke und Plattform beim Arzneimittelversandhandel“ (“Who distributed it? On the distinction between pharmacy and platform in the mail-order pharmaceutical trade”), in A&R 2024, p. 67
  • Ross oder Reiter – Zu den Grenzen des Krankenhausprivilegs (On the limits of the hospital privilege), A&R 2023, p. 75
  • Comment on the judgment of the Federal Court of Justice of January 12, 2023, file number IZR22219 I ZR 222/19 and file number I ZR 223/19, A&R 2023, p. 99 (together with Lukas Kalkbrenner)
  • Comment on the judgment of the ECJ of 22.12.2022 (C-530/20), Advertising with special offers for medicinal products, Arzneimittel und Recht (A&R) 2023, p. 38
  • Rabatte und Skonti auf Großhandelszuschläge – die Zweite (Discounts and rebates on wholesale surcharges – second part), Arzneimittel und Recht (A&R) 2021, p. 303
  • Wenn sich Mitarbeiter weigern – Was Sie zur Corona-Impfung Ihres Personals wissen sollten (When staff refuses – What you should know about Corona vaccination of your staff), Aktueller Wirtschaftsdienst für Apotheker, June 2021, p. 10 et seq. (together with Andreas Schubert)
  • Comment on the judgment of the ECJ of October 1, 2020 (Case C-649/18), (together with Anne Bongers-Gehlert), Arzneimittel und Recht (A&R) 2020, p. 235
  • Grenzen der Zusammenarbeit nach der Neuregelung des Vertriebswegs für Hämophilie-Präparate (Limits of cooperation after the reorganization of the distribution channel for hemophilia preparations), Arzneimittel & Recht, p. 175
  • Datenschutz und der Vertrieb apothekenpflichtiger Arzneimittel über Amazon (Data protection and the distribution of pharmacy-only medicines via Amazon), Arzneimittel&Recht 2019, p. 249 (together with Lukas Kalkbrenner)
  • Betriebspflicht für nicht rentable Apotheke (Operating obligation for unprofitable pharmacy), comment on the judgment of the Koblenz Higher Regional Court of June 27, 2019 – case no. 1 U 1471/18, Arzneimittel&Recht 2019, p. 278 (together with Ilva Schiessel)
  • Wettbewerbsrechtliche Ahndung von DSGVO-Verstößen (Competitive penalty of DSGVO infringements), comment on the judgment of the Hamburg Higher Regional Court of 25.10.2018 – Ref. 3 U 66/17 (together with Lukas Kalkbrenner), Arzneimittel&Recht 2019, p. 35
  • Comment on the judgment of the BGH of April 26, 2018 (I ZR 121/17), (together with Anne Bongers-Gehlert), Arzneimittel und Recht (A&R) 2018, p. 268
  • Comment on the judgment of the ECJ of March 1, 2018 (C-297/16), (together with Anne Bongers-Gehlert), Arzneimittel und Recht (A&R) 2018, p. 81
  • Die datenschutzrechtliche Bewertung der Einbindung von WhatsApp in die Arzneimittelvorbestellung (The data protection evaluation of the integration of WhatsApp into drug pre-ordering), Arzneimittel&Recht 2018, p. 3 (together with Lukas Kalkbrenner)
  • Die markenrechtliche Erschöpfung beim Parallelimport von Arzneimitteln [Trade Mark Exhaustion in the case of Parallel Imports of Drugs], published by Carl Heymanns Verlag, 2005
Overview

Articles by Morton Douglas

All articles